Durvalumab: all 557 studies that test it
Page 6 of 6. Open to participants first (117), then studies with results posted, then the rest; newest registration first within each.
- Biomarker-based Study in R/M SCCHNActive, not recruitingNCT03088059Phase 2
- SGI-110 Plus Durvalumab/Tremelimumab in SCLCCompletedNCT03085849Phase 1
- Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell LymphomaStatus unknownNCT03054532Phase 2
- Durvalumab, Cetuximab and Radiotherapy in Head Neck CancerStatus unknownNCT03051906Phase 1/2
- Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract CancerActive, not recruitingNCT03046862Phase 2
- A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical ResectionWithdrawnNCT03038477Phase 2
- Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung CancerTerminatedNCT03030131Phase 2
- Pulmonary sarcomatoid_MEDI4736+TremeCompletedNCT03022500Phase 2
- Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the LiverCompletedNCT03005002Phase 1
- Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant ExposureCompletedNCT02997995Phase 2
- Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell CarcinomaTerminatedNCT02997332Phase 1
- Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral CavityWithdrawnNCT02993991Phase 1
- Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal CancerActive, not recruitingNCT02983578Phase 2
- A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced MalignanciesCompletedNCT02978482Phase 1
- Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate CancerWithdrawnNCT02966587Phase 2
- Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal CancerActive, not recruitingNCT02962063Phase 1/2
- Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid TumorsTerminatedNCT02938793Phase 2
- Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)WithdrawnNCT02885727Phase 2
- Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.CompletedNCT02882308Phase 2
- Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia MyelofibrosisWithdrawnNCT02871323Phase 1
- Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic CancerWithdrawnNCT02868632Phase 1
- A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent GlioblastomaCompletedNCT02866747Phase 1/2
- Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast CancerActive, not recruitingNCT02826434Phase 1
- MEDI4736 Combinations in Metastatic Renal Cell CarcinomaCompletedNCT02819596Phase 2
- Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before SurgeryActive, not recruitingNCT02812420Early Phase 1
- Study of Azacitidine and Durvalumab in Advanced Solid TumorsCompletedNCT02811497Phase 2
- Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast CancerCompletedNCT02802098Early Phase 1
- Durvalumab in Pediatric and Adolescent PatientsCompletedNCT02793466Phase 1
- Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal CancersCompletedNCT02777710Phase 1
- Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell CarcinomaCompletedNCT02762006Phase 1
- A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic CancerCompletedNCT02734160Phase 1
- Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)Active, not recruitingNCT02726997Phase 1/2
- Pilot Study of Durvalumab and Vigil in Advanced Women's CancersCompletedNCT02725489Phase 2
- Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast CancerCompletedNCT02685059Phase 2
- Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy TrialActive, not recruitingNCT02678182Phase 2
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedNCT02664935Phase 2
- Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving TrastuzumabCompletedNCT02649686Phase 1
- Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic CancersCompletedNCT02639026Phase 1
- Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer PatientsCompletedNCT02628132Phase 1/2
- Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid TumoursCompletedNCT02617277Phase 1
- A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)Status unknownNCT02588131Phase 2
- A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic MalignanciesCompletedNCT02572687Phase 1
- A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid TumorsTerminatedNCT02556463Phase 1
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerActive, not recruitingNCT02546661Phase 1
- Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy RegimensActive, not recruitingNCT02537418Phase 1
- Adjuvant Durvalumab for Esophageal CancerStatus unknownNCT02520453Phase 2
- MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.CompletedNCT02503774Phase 1
- Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid TumorsCompletedNCT02301130Phase 1
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingNCT02299999Phase 2
- A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck CancerCompletedNCT02262741Phase 1
- A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid TumorsCompletedNCT02261220Phase 1
- A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid TumorsCompletedNCT02221960Phase 1
- Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ MesotheliomaCompletedNCT02141347Phase 1
- Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic SyndromeCompletedNCT02117219Phase 1
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsCompletedNCT02117167Phase 2
- MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).CompletedNCT02088112Phase 1
- A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid TumoursCompletedNCT01938612Phase 1